ANTXR1 and neoplasm: To date, major CAF-targeting strategies include decreasing CAFs in TME through CAR-T-cell therapy (58), a monoclonal antibody targeting fibroblast activation protein and tumor endothelial marker 8 (59), reducing immunosuppressive functions of CAFs to achieve greater T-cell accessibility to tumor cells and increased sensitivity to therapeutic approaches, decreasing the immunosuppressive characteristics of CAFs so that improving T cell accessibility to tumor cells and increasing sensitivity to therapeutic approaches.